Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation

Next Previous
X
Search
Trial Profile

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Rimiducid
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms CASPALLO

    • Most Recent Events

    • 11 Apr 2018 According to a Bellicum Pharmaceuticals media release, status changed from suspended to active, no longer recruiting.
    • 11 Apr 2018 According to a Bellicum Pharmaceuticals media release, the company announces the U.S. Food and Drug Administration has lifted the clinical hold on studies of BPX-501 in the U.S. and will be working with U.S. clinical sites to resume patient recruitment based on the amended protocols.
    • 13 Mar 2018 According to a Bellicum Pharmaceuticals media release, company has submitted a full response to the FDA clinical hold notification, including requested changes to study protocols to provide guidelines for comprehensive monitoring and management of neurologic adverse events associated with hematopoietic stem cell transplants.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top